HAE

Haemonetics Corporation Healthcare - Medical Devices Investor Relations →

YES
23.3% BELOW
↓ Approaching Was -21.6% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $76.37
14-Week RSI 20 📉
Rel. Volume (14w) This week's trading vs. the 14-week average 1.2x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.65 — Sellers winning

Haemonetics Corporation (HAE) closed at $58.58 as of 2026-03-20, trading 23.3% below its 200-week moving average of $76.37. This places HAE in the extreme value zone. The stock is currently moving closer to the line, down from -21.6% last week. With a 14-week RSI of 20, HAE is in oversold territory.

Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.65 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.

Over the past 1771 weeks of data, HAE has crossed below its 200-week moving average 39 times. On average, these episodes lasted 15 weeks. Historically, investors who bought HAE at the start of these episodes saw an average one-year return of +5.1%.

With a market cap of $2.7 billion, HAE is a mid-cap stock. The company generates a free cash flow yield of 12.2%, which is notably high. Return on equity stands at 19.3%, a solid level. The stock trades at 3.0x book value.

The company has been aggressively buying back shares, reducing its share count by 5.7% over the past three years.

Over the past 33.2 years, a hypothetical investment of $100 in HAE would have grown to $430, compared to $2683 for the S&P 500. HAE has returned 4.5% annualized vs 10.4% for the index, underperforming the broader market over this period.

Free cash flow has been growing at a 23.4% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: HAE vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After HAE Crosses Below the Line?

Across 39 historical episodes, buying HAE when it crossed below its 200-week moving average produced an average return of +3.2% after 12 months (median +0.0%), compared to +20.1% for the S&P 500 over the same periods. 49% of those episodes were profitable after one year. After 24 months, the average return was +17.9% vs +36.2% for the index.

Each line shows $100 invested at the moment HAE crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

HAE has crossed below its 200-week MA 39 times with an average 1-year return of +5.1% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Apr 1992May 199236.6%+20.0%+733.1%
Apr 1993Apr 199310.5%+13.3%+594.3%
Apr 1994May 1994613.6%-4.5%+610.1%
Jun 1994Oct 19941823.0%-3.9%+516.6%
Dec 1994Jun 19952826.3%-6.0%+529.0%
Jul 1995Jul 199510.5%-6.6%+516.6%
Oct 1995Aug 19964317.0%-4.2%+550.9%
Oct 1996Jun 19973717.1%-4.9%+555.4%
Jul 1997Sep 19971011.3%-14.9%+535.4%
Oct 1997Mar 19982524.0%+3.3%+589.2%
Apr 1998Sep 19982115.3%-10.4%+569.5%
Oct 1998Oct 199810.1%+11.7%+567.1%
Feb 1999May 19991318.9%+44.7%+581.7%
Jul 1999Jul 199910.7%+28.6%+562.4%
Jul 2002Aug 200234.4%-25.2%+378.2%
Sep 2002Jan 20047135.5%-14.0%+353.4%
May 2004May 200433.1%+52.3%+348.5%
Jul 2004Jul 200410.4%+51.2%+332.8%
Mar 2009May 200962.2%+10.2%+128.7%
Oct 2009Nov 200912.3%+6.1%+127.5%
May 2010Jun 201010.3%+23.6%+119.0%
Jun 2010Jun 201010.1%+17.5%+118.1%
Aug 2010Aug 201033.0%+13.9%+122.3%
Nov 2011Nov 201114.8%+49.0%+113.0%
Mar 2014Aug 20141911.8%+37.7%+82.4%
Aug 2014Oct 201495.6%+0.7%+64.1%
Aug 2015Nov 20166431.3%-3.6%+56.5%
Aug 2020Aug 202012.8%-26.7%-26.6%
Sep 2020Sep 202010.9%-15.3%-29.3%
Apr 2021May 202311052.2%-19.9%-13.2%
Jun 2023Jul 202353.1%+1.0%-30.1%
Nov 2023Nov 202310.8%+4.4%-28.5%
Jan 2024Jan 202410.4%-1.7%-28.1%
Jan 2024Mar 2024910.9%-12.9%-27.9%
Aug 2024Nov 2024138.4%-29.9%-24.0%
Dec 2024Dec 202411.4%+6.3%-22.3%
Jan 2025Jun 20252423.6%-1.8%-20.3%
Jul 2025Nov 20251835.6%N/A-19.3%
Jan 2026Ongoing10+24.2%Ongoing-18.8%
Average15+5.1%

Frequently Asked Questions

Is HAE below its 200-week moving average?

Yes. As of 2026-03-20, Haemonetics Corporation (HAE) is trading 23.3% below its 200-week moving average of $76.37. The current price is $58.58.

What is HAE's 200-week moving average price?

Haemonetics Corporation's 200-week moving average is $76.37 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when HAE drops below its 200-week moving average?

HAE has crossed below its 200-week moving average 39 times in our data. On average, buying at that moment produced a one-year return of +5.1%. These dips have historically been decent entry points. These episodes lasted 15 weeks on average.

Is HAE a good value right now?

Here's what our data says about HAE as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 20 (oversold). Free cash flow yield is 12.2%. Return on equity is 19.3%. Price-to-book is 3.0x. This is not a buy or sell recommendation — always do your own research.

How does HAE compare to the S&P 500?

Over the past 33.2 years, $100 invested in HAE would have grown to $430, compared to $2683 for the S&P 500. That's 4.5% annualized vs 10.4% for the index. HAE has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20